Category Pharmaceuticals
Psychedelics, Ethics, and the Commercial Determinants of Health
Daniel Rosenbaum and Daniel Z. Buchman draw attention to commercial involvement in psychedelic research and to the population health risks associated with this involvement.
Alberta’s Recovery-Based Approach to the Opioid Crisis
Shyanne Dougherty questions the goal and the likely effectiveness of the Alberta UCP government’s supposed “recovery-based” approach to the opioid crisis.
Mind the Ethical Gap in AI-Powered Drug Discovery
Dessislava Fessenko shows that while artificial intelligence might revolutionize drug development, its use comes with risks and potential ethical implications. Iterative ethics oversight from the get-go is needed to address the looming concerns.
Independence, Influence & Power: Canada’s Failed Medicine Pricing Reforms
Matthew Herder presents his opening statement to the House of Commons’ Standing Committee on Health on May 2, 2023. In February, Herder resigned from the Patented Medicine Prices Review Board (PMPRB).
Whose Responsibility Are Ethical Issues in Phase 1 Research?
Dessislava Fessenko reveals that ethical concerns surrounding the participation of healthy volunteers in Phase 1 clinical trials have deep roots in broader social conditions, which require social policy responses.
Impact Ethics 